12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

Momenta, Baxter deal

Baxter and Momenta said they will partner to co-develop and commercialize two undisclosed biosimilars worldwide. Baxter has the option to add up to four additional biosimilars to the deal. Momenta will receive $33 million up front and is eligible for option payments...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >